Literature DB >> 11162648

Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I.

R M Snapka1, H Gao, D R Grabowski, D Brill, K K Chan, L Li, G C Li, R Ganapathi.   

Abstract

Topoisomerase IIbeta knockout mouse cells (beta-/-) were found to have only slight resistance to m-AMSA, a dual topoisomerase IIalpha-IIbeta poison, as compared to wild-type cells (beta+/+) during 1 h or 3 day exposures to the drug. In contrast, the beta-/- cells were greater than threefold resistant to XK469, a selective topoisomerase IIbeta poison during three day drug exposures (beta+/+ IC(50) = 175 microM, beta-/- IC(50) = 581 microM). Short term (1 h) exposure to XK469 was not cytotoxic to either beta-/- or beta+/+ cells, suggesting that anticancer therapy with XK469 may be more efficacious if systemic levels can be prolonged. During studies on topoisomerase activity in nuclear extracts of the beta+/+ and beta-/- cells, we found evidence that XK469 is a weak topoisomerase I catalytic inhibitor. The high IC(50) for topoisomerase I inhibition (2 mM) suggests that topoisomerase I is not a significant target for XK469 cytotoxicity. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11162648     DOI: 10.1006/bbrc.2001.4249

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor.

Authors:  Amin M Alousi; Ramesh Boinpally; Richard Wiegand; Ralph Parchment; Shirish Gadgeel; Lance K Heilbrun; Antionette J Wozniak; Pamela DeLuca; Patricia M LoRusso
Journal:  Invest New Drugs       Date:  2006-11-11       Impact factor: 3.850

2.  Nitric oxide inhibits ATPase activity and induces resistance to topoisomerase II-poisons in human MCF-7 breast tumor cells.

Authors:  Birandra K Sinha; Ashutosh Kumar; Ronald P Mason
Journal:  Biochem Biophys Rep       Date:  2017-04-20

3.  A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.

Authors:  Samir D Undevia; Federico Innocenti; Jacqueline Ramirez; Larry House; Apurva A Desai; Linda A Skoog; Deepti A Singh; Theodore Karrison; Hedy L Kindler; Mark J Ratain
Journal:  Eur J Cancer       Date:  2008-07-21       Impact factor: 9.162

4.  R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.

Authors:  Wei Peng Yong; Tae Won Kim; Samir D Undevia; Federico Innocenti; Mark J Ratain
Journal:  Eur J Cancer       Date:  2009-05-21       Impact factor: 9.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.